← All diseases
Cancer
Lung cancer (non-small cell)
Do you want to receive a message when there is new research on Lung cancer (non-small cell)? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, one sentence appears above each publication explaining what was studied — and you'll be notified as soon as new research about Lung cancer (non-small cell) is available. View what Premium costs.
Publications and studies (3237)
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Clinical indications and future directions of carbon-ion radiotherapy: a narrative review. (2024/10/01) ♡
- Treatment of Unsuspected T4 Non-Small Cell Lung Cancer With Additional Intrapulmonary Nodules. (2024/09/30) ♡
- Metabolic Reprogramming of Phospholipid Fatty Acids as a Signature of Lung Cancer Type. (2024/09/28) ♡
- Social Vulnerability Index Is Associated With Major Morbidity After Lung Resection. (2024/09/28) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The role of DNA methylation and DNA methyltransferases (DNMTs) as a potential biomarker and therapeutic target in non-small cell lung cancer (NSCLC). (2024/09/27) ♡
- Sarcopenia predicts immune-related adverse events due to anti-PD-1/PD-L1 therapy in patients with advanced lung cancer. (2024/09/23) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. New advances in lung cancer treatment: Efficacy, safety, and future research directions. (2024/09/21) ♡
- The association between postdiagnosis smoking cessation and survival in advanced non-small cell lung cancer patients in Southern Taiwan: A retrospective cohort study. (2024/09/17) ♡
- Alkaloids of Aconiti Lateralis Radix Praeparata inhibit growth of non-small cell lung cancer by regulating PI3K/AKT-mTOR signaling and glycolysis. (2024/09/11) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Integration of clinical and blood parameters into risk prognostication for patients receiving immunochemotherapy for extensive stage small cell lung cancer: real-world data from two centers. (2024/09/11) ♡
- Synthesis of quinoxalines and assessment of their inhibitory effects against human non-small-cell lung cancer cells. (2024/09/09) ♡
- Acyl-coenzyme a binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance. (2024/09/06) ♡
- Peripheral Inflammation Featuring Eosinophilia or Neutrophilia Is Associated with the Survival and Infiltration of Eosinophils within the Tumor among Various Histological Subgroups of Patients with NSCLC. (2024/09/03) ♡
- Toosendanin Induces Lung Squamous Cell Carcinoma Cell Apoptosis and Inhibits Tumor Progression via the BNIP3/AMPK Signaling Pathway. (2024/09/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Therapeutic potential of ethoxy mansonone G: A comprehensive exploration of its anticancer actions in breast cancer, colorectal cancer, and non-small cell lung carcinoma. (2024/09/01) ♡
- Isotosendanin exerts anti-tumor effects in NSCLC by enhancing the stability of SHP-2 and inhibiting the JAK/STAT3 pathway. (2024/09/01) ♡
- Centipeda minima and 6-O-angeloylplenolin enhance the efficacy of immune checkpoint inhibitors in non-small cell lung cancer. (2024/09/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A randomized, open-label phase II study on the preventive effect of goshajinkigan against peripheral neuropathy induced by paclitaxel-containing chemotherapy: The OLCSG2101 study protocol. (2024/09/01) ♡
- Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. The nutrition-related adverse events associated with immune checkpoint inhibitor treatment for patients with non-small cell lung cancer: A systematic review. (2024/09/01) ♡
- MiRNA-153 attenuates progression of non-small cell lung cancer through targeting positive regulatory/SET domain 2. (2024/09/01) ♡
- The Geriatric Nutritional Risk Index as a prognostic factor in patients treated with immune checkpoint inhibitors with non-small-cell lung cancer. (2024/08/31) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. AXL and SHC1 confer crizotinib resistance in patient-derived xenograft model of ALK-driven lung cancer. (2024/08/30) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Combined RET and MEK Inhibition as a Treatment for RET Fusion-Positive NSCLC With Acquired BRAF Fusion: A Case Report. (2024/08/28) ♡
- Brief Report: Impact of Maintenance Pemetrexed Cessation on Clinical Outcomes of Patients With Metastatic Nonsquamous NSCLC. (2024/08/24) ♡
- Author Correction: Predictive value of inflammation and nutritional index in immunotherapy for stage IV non-small cell lung cancer and model construction. (2024/08/22) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Unlocking the predictive power of imaging biomarkers: predicting immune checkpoint therapy response in non-small cell lung cancer through baseline tumour vessel perfusions. (2024/08/21) ♡
- Baseline tumour vessel perfusion as a non-invasive predictive biomarker for immune checkpoint therapy in non-small-cell lung cancer. (2024/08/21) ♡
- SLL-1A-16 suppresses proliferation and induces autophagy in non-small-cell lung cancer cells via the AKT/mTOR signaling pathway. (2024/08/17) ♡
- RP11-874 J12.4 promotes erlotinib resistance in non-small cell lung cancer via increasing AXL expression. (2024/08/15) ♡
- Phosphoenolpyruvate carboxykinase 2-mediated metabolism promotes lung tumorigenesis by inhibiting mitochondrial-associated apoptotic cell death. (2024/08/09) ♡
- Peri- and postoperative morbidity and mortality in older patients with non-small cell lung cancer: a matched-pair study. (2024/08/08) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Adverse Events in Osimertinib Treatment for EGFR-Mutated Non-Small-Cell Lung Cancer: Unveiling Rare Life-Threatening Myelosuppression. (2024/08/06) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Saponin Ⅰ from Shuitianqi () inhibits metastasis by negatively regulating the transforming growth factor-β1/Smad7 network and epithelial-mesenchymal transition in the intrahepatic metastasis Bagg's Albino/c mouse model. (2024/08/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Antibody-drug conjugates treatment of small cell lung cancer: advances in clinical research. (2024/08/01) ♡
- Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Comparative Efficacy and Safety of Immunotherapy on Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Network Meta-Analysis. (2024/08/01) ♡
- The association of nutritional and inflammatory biomarkers with overall survival in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors. (2024/08/01) ♡
- The influence of nutritional status, lipid profile, leptin concentration and polymorphism of genes encoding leptin and neuropeptide Y on the effectiveness of immunotherapy in advanced NSCLC patients. (2024/08/01) ♡
- Cytotoxicity of Benzofuran-Containing Simplified Viniferin Analogues. (2024/08/01) ♡
- Combining dynamics of serum inflammatory and nutritional indicators as novel biomarkers in immune checkpoint inhibitor treatment of non-small-cell lung cancer with bone metastases. (2024/07/30) ♡
- Predictive value of inflammation and nutritional index in immunotherapy for stage IV non-small cell lung cancer and model construction. (2024/07/30) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Advanced Lung Cancer Inflammation Index: A Novel Comprehensive Biomarker of Host Status for Patients with Metastatic Colorectal Cancer. (2024/07/30) ♡
- Using the combined C-reactive protein and controlling nutritional status index for elderly non-small cell lung cancer. (2024/07/30) ♡
- Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer. (2024/07/30) ♡
- Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experience. (2024/07/30) ♡
- Living with low muscle mass and its impact throughout curative treatment for lung cancer: A qualitative study. (2024/07/29) ♡
- Plain language summary of a clinical study: anamorelin for treatment of Japanese people with non-small cell lung cancer and cachexia. (2024/07/29) ♡
- Psychiatric Comorbidities and Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer. (2024/07/29) ♡
- Utility of PET for Nodal Staging in Subsolid Clinical Stage IA (T1 N0) Lung Adenocarcinoma. (2024/07/26) ♡
- A new classification of upper gastrointestinal toxicity induced by immunotherapy: from endoscopic and pathological insights to clinical management. (2024/07/25) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Loss of the tumour suppressor LKB1/STK11 uncovers a leptin-mediated sensitivity mechanism to mitochondrial uncouplers for targeted cancer therapy. (2024/07/25) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.